Abstract-Renal denervation has shown promise in the treatment of resistant hypertension, although the mechanisms underlying the blood pressure (BP) reduction remain unclear. In a translational study of spontaneously hypertensive rats (n=7, surgical denervation) and resistant hypertensive human patients (n=8; 5 men, 33-71 years), we examined the relationship among changes in BP, sympathetic nerve activity, and cardiac and sympathetic baroreflex function after renal denervation. In humans, mean systolic BP (SBP; sphygmomanometry) and muscle sympathetic nerve activity (microneurography) were unchanged at 1 and 6 months after renal denervation (P<0.05). Interestingly, 4 of 8 patients showed a 10% decrease in SBP at 6 months, but sympathetic activity did not necessarily change in parallel with SBP. In contrast, all rats showed significant and immediate decreases in telemetric SBP and lumbar sympathetic activity (P<0.05), 7 days after denervation. Despite no change in SBP, human cardiac and sympathetic baroreflex function (sequence and threshold techniques) showed improvements at 1 and 6 months after denervation, particularly through increased sympathetic baroreflex sensitivity to falling BP. This was mirrored in spontaneously hypertensive rats; cardiac and sympathetic baroreflex sensitivity (spontaneous sequence and the Oxford technique) improved 7 days after denervation. The more consistent results in rats may be because of a more complete (>90% reduction in renal norepinephrine content) denervation. We conclude that (1) renal denervation improves BP in some patients, but sympathetic activity does not always change in parallel, and (2) baroreflex sensitivity is consistently improved in animals and humans, even when SBP has not decreased. Determining procedural success will be crucial in advancing this treatment modality. 
I
n Europe and the United States, ≈15% to 30% of adults diagnosed with hypertension are resistant to pharmacological intervention. 1, 2 That is, their blood pressure (BP) fails to meet target levels despite treatment with >3 antihypertensive medications. This is termed drug-resistant hypertension and has been highlighted as a growing problem worldwide. 1, 3 Drugresistant hypertension particularly emphasizes the inadequacies of current pharmacological-based treatment regimes in a significant proportion of patients. 4 It is not surprising, therefore, that device-based therapy developed from classic hypotheses regarding sympathetic activity and hypertension [5] [6] [7] [8] has received renewed focus as a treatment for difficult-to-control hypertension. [9] [10] [11] [12] Among these, catheter-based renal denervation (RDN) has been shown to safely and effectively decrease BP in patients with resistant hypertension. 9, 11 According to the Symplicity trial investigators, RDN decreased systolic BP (SBP; n=46, −20 mm Hg) in resistant hypertensives as early as 1 month postprocedure 13 and continued to decrease and maintain a lower BP for ≤24 months (n=18). 14 The Symplicity-2 investigators purport a 83.7% success rate (a reduction in SBP >10 mm Hg) at 6 months post-RDN. 9 Despite the recent accumulation in publications relating to RDN in humans, 9, 11, [13] [14] [15] [16] [17] [18] as well as many previous animal studies, [5] [6] [7] 19 little is known of the mechanisms by which RDN reduces BP. It has been hypothesized that decreased renal afferent input into the brain stem reduces reflex-evoked increases in both sympathetic nerve activity (SNA) and BP. 20 In this context, selective renal afferent denervation (dorsal rhizotomy) in rats with chronic renal failure abolishes hypertension in these animals. 21 Furthermore, both single-unit and multiunit SNA decreased in patients who responded to RDN. 22 Conversely,
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Brinkmann et al 18 reported that neither average group BP nor muscle SNA (MSNA) was altered in 11 resistant hypertensive patients studied 3 to 6 months after RDN. This raises the important issue of preprocedural screening to determine responders. Interestingly, cardiac baroreflex function has been demonstrated to improve in some humans 20 and animals who respond to RDN with a decrease in SBP. 23 Changes in baroreflex function after RDN may reflect a decrease in renal nerve afferent input into the brain stem. Consistent with this hypothesis, selective renal afferent denervation resulted in improved cardiac baroreflex sensitivity in spontaneously hypertensive (SH) rats. 24 Despite studies reporting either a change in baroreflex function in humans after RDN 20 or a lack of change, 18 interindividual differences in the response of the cardiac and sympathetic baroreflex have been overlooked. It is possible that improvements in baroreflex function are linked to reduced SNA and BP outcome after RDN, especially because chronic carotid sinus stimulation is antihypertensive. 12 To gain insight into the depressor mechanisms of RDN and because translational physiology is essential for our understanding of hypertension, we completed the following aims in both SH rats and human resistant hypertensive patients. We examined whether changes in SNA and baroreflex control of falling and rising BP were temporally related to changes in BP after RDN in SH rats and whether these data were mirrored in resistant hypertensive humans receiving catheter-based RDN.
Methods
Human Study
Patients
After the study received local NHS (National Health Service) and Trust ethical approval, we recruited 13 resistant hypertensive patients for treatment using the Symplicity catheter-based RDN method. Patients were recruited from our specialist hypertension clinic and were defined as drug-resistant hypertensives only after their treatments were optimized/thoroughly screened for white coat hypertension as per the National Institute of Clinical Excellence guidelines in the United Kingdom for the management of BP. All patients were either taking (5/8) or deemed intolerant to spironolactone (a potassium-sparing diuretic that is also an aldosterone receptor antagonist), suggesting that the hypertension was not secondary to subclinical hyperaldosteronism. Drug-resistant hypertension was defined as a clinic SBP >160 mm Hg or 24-hour ambulatory SBP >135 mm Hg, despite treatment with ≥3 antihypertensive medications including a diuretic. 3 Full pre-and post-RDN data were achieved for 8 of 13 patients; 2 patients had a weight loss of >5 kg, making interpretation of changes in MSNA invalid; 2 patients failed to report for followup; and finally, 1 patient was excluded because of stroke during the follow-up period. In 1 patient, the microneurography recordings could not be completed; therefore, data for MSNA and baroreflex data are presented for 7 patients. Table 1 outlines patient demographics and antihypertensive medication (see Table S1 in the online-only Data Supplement for details and comorbidities) for the 8 completed subjects. Body mass remained stable throughout the study (Table 2) . Medications did not change in 6 of 8 patients. In 1 patient, spironolactone was stopped, and the dose of doxazosin was decreased within the first 6 months postprocedure because the patient showed a significant decrease in SBP with symptoms of postural hypotension (participant 6). The other patient had doses of antihypertensive medications increased 1 month postprocedure because their BP persistently increased after RDN (participant 5). Drug adherence was assessed throughout the study via a patient self-reporting process.
Catheter-Based RDN
RDN was completed using the Symplicity Catheter System (Medtronic). Pain during the procedure was controlled using titrated doses of intravenous fentanyl and midazolam. A 6F femoral arterial sheath was sited under local anesthesia. The procedure was performed under anticoagulation with a bolus of intravenous heparin (100 IU/kg); the activated clotting time was checked 30 minutes into the procedure, and a further intravenous heparin bolus was administered, if required, to maintain an acute clotting time of >250 ms. Four to 8 radiofrequency ablations along both main renal arteries were applied (maximum 8 W, maximum 75°C for 2 minutes). The distance between ablations was >0.5 mm. The catheter was rotated ≈60° between ablations, which were applied from distal to proximal in a spiral pattern. Patients were loaded on aspirin (300 mg) before the procedure and discharged with a 4-week course of aspirin (75 mg) once daily, unless already on longterm antiplatelet therapy. Patients were advised to continue all of their current antihypertensive medications on discharge.
Study Day Measurements and Protocol
All studies were performed in our Clinical Research Laboratory at the Bristol Heart Institute. Patients reported to the laboratory before and at 1 and 6 months after procedure. Three patients attended an additional study visit at 3 months, and these data are presented individually rather than averaged (Figure 2 ). Patients were asked to (1) take their antihypertensive medication as usual and (2) abstain from caffeine/alcohol/additional pain killers (eg, ibuprofen) and intense exercise 24 hours before the study day. All patients were studied at the same time of day on repeat visits. 
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After seated rest, clinic BP was assessed using standard automated sphygmomanometry. 25 Average clinic cuff SBP (3 readings) was used as outcome BP for success of RDN. Patients were asked to lie supine for neuro-cardiovascular assessment. Beat-by-beat BP was measured using a Finometer (Finapres medical systems), calibrated to the BP measured in the arm using an automated cuff. A 3-lead ECG was used for continuous monitoring of heart rate.
Multiunit MSNA was measured from the right peroneal nerve at the fibular head using tungsten microelectrodes (FHC Inc, Bowdoin, ME). Cardiac baroreflex function was measured using the spontaneous sequential technique, 26 and sympathetic baroreflex sensitivity was measured using the spontaneous threshold technique. 27, 28 For further methods, data, and statistical analyses regarding microneurography and baroreflex sensitivity, please see the online-only Data Supplement Methods.
Animal Study
Animal experiments were conducted in accordance with the UK Animals (Scientific Procedures) Act 1986 and associated guidelines. Adult (12 weeks; n=7) SH rats bred in the University of Bristol Animal Services Unit were used. See online-only Data Supplement Methods for surgical procedures.
Data Collection
Arterial pressure and heart rate were recorded for 24 hours a day as described in the online-only Data Supplement Methods. To avoid movement artifact, lumbar SNA (LSNA) was recorded for an hour at the same time each day while the rats (undisturbed in their home cage) were observed to be quiescent. On days 2 and 7, rats were exposed to a brief burst of high frequency noise, which produces a stress increase in sympathetic outflow. The magnitude of the response to noise stress was used to check whether the LSNA signal remained stable and responsive throughout the experiment. On experimental days 1 and 8, baroreflex function measured using venous infusions of vasoactive solutions were used to produce increases and decreases in BP 29 (see online-only Data Supplement Methods).
Results
Hemodynamic Response to RDN in SH Rats and Human Hypertensives
Surgical RDN in SH rats was associated with a >90% reduction in renal tissue noradrenaline content (31±7 pg/100 µg protein RDN versus 443±45 pg/100 µg protein; P>0.01). Mean SBP, diastolic BP, and mean arterial pressure decreased within 24 hours of RDN by an average of 10±2 mm Hg (P<0.05), and this level was maintained for the full 10 days of recording. Over a similar time course, moderate reductions in LSNA of 25±11% could be observed (values averaged over 3 days preprocedure and 6-9 days postprocedure; Table 3 ; P<0.05). Figure 1 shows the group (rat) average arterial pressure and LSNA response to RDN across the full recording period. Table 2 outlines the group mean hemodynamic response to RDN in resistant hypertensive humans, 1 and 6 months postprocedure. In contrast to the SH rats, mean clinic BPs did not change after RDN (n=8; 1 and 6 months post-RDN; P>0.05). However, when individuals were considered, clear responders (decrease in clinic SBP >10 mm Hg) and nonresponders became evident ( Figure 2 ). In fact, 50% of the patients responded with a >10 mm Hg drop in SBP at 1 and 6 months post-RDN. There was no change in group mean stroke volume, cardiac output, heart rate, total peripheral resistance, and MSNA 1 month or 6 months post-RDN (P>0.05). Regarding interindividual responses in MSNA, 4 of 7 patients responded with a decrease (ie, >10% fall) in MSNA at 6 months. The individuals with a change in MSNA at 6 months post-RDN were not necessarily those with a change in SBP. One individual who had the highest decrease in SBP (−44 mm Hg) had an increase in MSNA (+28 bursts/100 heart beats; Figure 2 , patient 6M). Changes in MSNA at 1 and MSNA, bursts/100 heart beats 67±7 63±6 64±9
MSNA, bursts/min 38±2 39±3 38±4
Clinic blood pressures are taken on the same day as the study day with an automated cuff (mean of 3). BMI indicates body mass index; CO, cardiac output; DBP, diastolic blood pressure; DBPv, DBP variability; fDBP, finometer-based DBP; fMAP, finometer-based mean arterial pressure; fSBP, finometer-based systolic blood pressure; HR, heart rate; HRv, HR variability; MAP, mean arterial pressure; MSNA, muscle sympathetic nerve activity; RDN, renal denervation; SBP, systolic blood pressure; SBPv, SBP variability; SV, stroke volume; and TPR, total peripheral resistance. Data shown are mean of 3 baseline days and days 6 to 9 post-RDN (mean±SEM). DBP indicates diastolic blood pressure; HR, heart rate; MBP, mean blood pressure; PI, pulse interval; RDN, renal denervation; SBP, systolic blood pressure; sBRS, spontaneous baroreflex sensitivity; and SH, spontaneously hypertensive. *P<0.05.
by guest on April 9, 2017 http://hyper.ahajournals.org/ Downloaded from 6 months did not correlate with changes in SBP at either 1 or 6 months after RDN (r=−0.14 and −0.23, respectively; P>0.05). There was no relationship between baseline MSNA and change in SBP at 1 or 6 months (r=0.05 and 0.07, respectively). In addition, we found no relationship between the number of ablations and the change in BP at 1 and 6 months (r=0.17 and 0.20).
Cardiac Baroreflex Sensitivity
In SH rats, cardiac baroreflex sensitivity was assessed using 2 methods. First, automated examination of spontaneous ramps in SBP and heart rate across the 24-hour recording period showed a significant increase in spontaneous cardiac baroreflex sensitivity from 0.64±0.03 to 0.74±0.02 ms/mm Hg (see Table 2 ; P<0.05), which again occurred very rapidly (within 24 hours) of the RDN surgery. Second, using vasoactive agents, the maximum gain of the baroreflex function curve increased ( Figure 3A ; −4.45±0.43 versus −5.77±0.56 bpm per mm Hg; P=0.028), which was because of both an improvement in the lower plateau of the curve (314±9 versus 289±15 bpm; P=0.036; Table S2 ) and a leftward shift in the BP50 (138±3 versus 131±4 mm Hg; P=0.021). Without a significant change in heart rate, the operating point moved toward the center of the cardiac curve, thereby improving the ability to buffer hypotensive swings in arterial pressure. The response of the cardiac baroreflex to RDN in resistant hypertensive humans mirrored that found in the SH rats. That is, the sensitivity (slope) of spontaneous baroreflex was increased at 6 months postprocedure compared with pre-RDN (pre, 6.7±1.9 ms/mm Hg versus post 6 months, 14.3±2.7 ms/mm Hg; Figure 3B ). At 1 month, there was a trend of an increase in cardiac baroreflex sensitivity (+4.4±1.8 ms/mm Hg; P=0.08). Figure 4B illustrates the change in cardiac baroreflex sensitivity in 1 patient (patient 6) who responded to RDN, with a decrease in SBP at 6 months postprocedure. Interestingly, 6 of 7 patients responded with an increase in cardiac baroreflex sensitivity even if SBP did not change as was the case in 4 patients. It should be noted that we did attempt to examine whether the cardiac baroreflex sensitivity changed in response to decreasing and increasing SBP separately. However, because there was a lack of cardiac sequences (≥4 heart beats) when either decreasing or increasing SBP was considered separately, we could not statistically examine whether the ability of the cardiac baroreflex to buffer either falling or rising BP improved after RDN. There was no relationship between the change in cardiac baroreflex sensitivity and the change in SBP at both 1 (r=0.12) and 6 months (r= 0.19).
Sympathetic Baroreflex Sensitivity
All SH rats responded with an increase in sympathetic baroreflex sensitivity (∆ 4.5±1.1%/mm Hg; P<0.05). This increase in gain was because of an increase in the upper curvature fitting parameter (0.29±0.05 versus 0.59±0.08; P<0.05; Table  S2 ), which corresponds to the ability to respond to falling BP. The response to rising BP was not significantly different (ie, Figure 3B shows the mean group sympathetic baroreflex curves for SH rats. Note (similar to the cardiac baroreflex) the left and downward shift in both the operating point and BP50 (centering point) of the SNA baroreflex curve after RDN, thereby ensuring that the baroreflex regulation of LSNA remained on the linear portion of the curve.
Analogous to the SH rats, sympathetic baroreflex sensitivity increased in the resistant hypertensive humans at 1 (Δ −1.7±0.4%/mm Hg; P<0.05) and 6 months (Δ −0.9±0.3%/ mm Hg; P<0.05) after RDN ( Figure 5 ). Figure 5B illustrates the change in sympathetic baroreflex sensitivity after RDN at 1 and 6 months in 1 patient (3F). Overall, there was an increase (>10%, P<0.05) in baroreflex sensitivity in 6 of 7 patients.
In humans, because baroreflex function is dependent on whether BP is increasing or decreasing, 30 we measured the sensitivity of the sympathetic baroreflex during falling and rising BPs separately. Similar to SH rats, we found that sympathetic baroreflex sensitivity during falling arterial pressures was significantly improved at 1 and 6 months after RDN (Δ −1.4±0.6%/mm Hg and Δ −1.76±0.4%/mm Hg; n=6/7; both P<0.05; Figure 5 ). However, sympathetic baroreflex sensitivity to rising pressure was unchanged at 1 and 6 months after RDN (Δ −0.6±0.4%/mm Hg and Δ 0.4±0.6%/mm Hg, respectively; P>0.05,). The change in total sympathetic baroreflex sensitivity and baroreflex sensitivity to rising BP were not related to the change in SBP at 1 or 6 months. There was a trend toward a correlation between the change in SBP at 6 months and the increase in spontaneous baroreflex sensitivity to falling BP at 1 month (r=0.56; P=0.09).
Discussion
The novel findings of the current study were that after RDN there was (1) a small but consistent fall in SBP in SH rats, whereas by guest on April 9, 2017 http://hyper.ahajournals.org/ Downloaded from only 4 of 8 human patients responded with a >10 mm Hg fall in SBP at 6 months; (2) a decrease in BP in SH rats was mirrored by a reduction in SNA. In contrast, in human resistant hypertensive patients who responded with a decrease in SBP in response to RDN, MSNA did not necessarily fall; (3) an increase in cardiac and sympathetic baroreflex sensitivity was observed in both SH rats and human patients, which was not dependent on whether BP changed. In particular, sympathetic baroreflex control of falling BP improved in both SH rats and humans.
Temporal Response of BP and SNA to RDN
Essential hypertension is associated with elevated SNA in both animal models and humans. 31, 32 It is estimated that SNA is elevated in ≈50% of hypertensive patients. 32 In our cohort of hypertensive patients, MSNA was high in all patients compared with MSNA levels reported in normotensive individuals of a similar age/sex. 33, 34 Because elevated sympathetic activity is associated with target-organ damage, 35 it is crucial that any new interventional antihypertensive treatment, such as RDN, reduces SNA, as well as SBP. In all SH rats, we found that LSNA and SBP were decreased after RDN and that these changes occurred very rapidly (within 24 hours of RDN surgery). In contrast, only 4 of 8 resistant hypertensive patients exhibited a decrease in SBP at 6 months after the procedure. In 3 of 7 patients, the decrease in SBP was accompanied by a fall in MSNA. However, in 1 patient we found that MSNA was increased, despite a decrease in SBP, whereas in another there was an increase in SBP with no change in MSNA. Importantly, we found no relationship between the change in MSNA at 1 month and the change in SBP at 6 months, suggesting that a reduction in MSNA at 1 month is not necessarily predictive of a reduction in SBP at 6 months. The patient with largest reduction in SBP had an increase in MSNA at 1 month and continued to increase at 6 months after procedure. This suggests that changes in MSNA and SBP after RDN in resistant hypertensive humans are not always linked.
Brinkmann et al 18 recently reported similar results in which MSNA and SBP were not changed in parallel after RDN in resistant hypertensive patients. However, these patients had lower SBP and MSNA before RDN compared with patients in both our study and those included in the Symplicity trials. 9, 18, 22 Despite this, the SBP outcome data at 3 to 6 months after RDN reported by Brinkmann et al 18 (30% >10 mm Hg drop in SBP) are similar to that observed in the current study. In stark contrast to both our study and the recent study by Brinkmann et al, 18 Hering et al 22 demonstrate that both groupaverage multiunit and single-fiber MSNA are reduced alongside a decrease in SBP at 3 months after RDN.
RDN in SH rats has been previously shown to reduce SBP [5] [6] [7] as it has in other hypertensive models 19, 36, 37 and provided much of the basis for targeting the renal nerves in hypertensive humans. 16, 38 Unlike the consistency in rodents, RDN in humans may not always reduce BP as reported herein and previously. 18, 39, 40 Conversely, the Symplicity trial investigators report better BP outcomes, where the percentage of patients who responded to RDN was 87% at 12 months and ranged from 63% (crossover group) to 84% (original RDN group) at 6 months in Symplicity-1 and 2, respectively. Interestingly, we and others 18, 40 find stark differences in BP outcome after RDN compared with these large company-sponsored trials. A key point of difference between our study (and others) 40 and the Symplicity trials is that antihypertensive medications were altered in a large portion of the participants, which might explain why successful BP outcome is higher in the Symplicity investigations. The class or type of antihypertensive medications may significantly impact BP outcome because they have varying effects on the basal SNA and BP. 41 Conducting scientific studies on patients with the RDN procedure, whether with the Symplicity or other available catheters, is currently problematic. First, there are no prescreening processes that would allow identification of BP responders. This is essential from the standpoint of obtaining a more homogeneous cohort. Second, presently there is no on-table monitoring of procedural success of effective afferent and efferent fiber denervation. In our rat studies, nerve ablation was performed under direct visual inspection with phenol application. Furthermore, the degree of denervation was verified post hoc from the large reduction in noradrenaline content within the kidneys (>95%). Differences in the effectiveness of the RDN procedure between animals and humans might explain why BP reductions are more consistent in animals. The rare human studies that have assessed efficacy show reductions in renal noradrenaline spillover of ≈47%, but with wide variability. 11 Nevertheless, the technique does offer a way to monitor efferent denervation, for example, its longevity and whether any reinnervation of sympathetic nerves to the kidneys post-RDN occurs. However, given that the majority of our patients showed consistent improvement in baroreflex function (see below), we believe that our denervation was functionally efficacious. This leads us to conclude that RDN is beneficial for some but not all drug-resistant hypertensive patients and that preselection criteria are required.
Cardiac and Sympathetic Baroreflex Sensitivity
We found that improvements in cardiac and sympathetic baroreflex sensitivity occurred even in patients who did not demonstrate a BP response to RDN. Because successful RDN procedures in animals indicate an improvement in baroreflex function, 23, 24 we believe that improved baroreflex sensitivity supports interruption of renal afferent fibers. 24 However, because unilateral RDN improves baroreflex function in rats, it is possible that the baroreflex is more sensitive to changes in afferent input compared with the set point of BP itself (Schiller et al 42 Abstract). Consequently, even partial renal afferent denervation may cause improvements in baroreflex sensitivity but not resting BP.
Improvements in baroreflex control of BP are important to prevent large surges and falls in BP. Interestingly, we found that increased sympathetic baroreflex sensitivity in rats and humans was because of an increase in sensitivity to falling arterial pressure. Therefore, falling BP will be more effectively buffered by increments in SNA after RDN. Importantly, low baroreflex sensitivity is an independent predictor of mortality and major adverse cardiovascular-related events in hypertensive patients. 43 Improvements in baroreflex function after RDN may, therefore, directly improve mortality risk in these patients. This might be related to improvements in BP lability/variability, 44 a known risk for target organ damage, including stroke incidence. 45, 46 We measured BP variability over a 10-minute quiet resting period, which was unchanged after RDN at 1 and 6 months. However, this may not be a reliable estimation of BP variability over a 24-hour period, which is highly correlated to prognostic outcome in cardiovascular disease. Furthermore, improved baroreflex function might relieve patients of the orthostatic effects of some antihypertensive medications. Interestingly, increased sympathetic baroreflex sensitivity in humans at 1 month post-RDN was associated with reduced SBP at 6 months; this may act as an early predictor of successful treatment and provide a key mechanism for the depressor response.
In stark contrast to our data, Brinkmann et al 18 reported no change in either cardiac or sympathetic baroreflex sensitivity after RDN. We offer several explanations: first, our patients were more hypertensive at baseline (SBP difference ≈11 mm Hg). Second, Brinkmann et al, 18 in their study, followed up once between 3 and 6 months, whereas we made 2 postprocedural measurements at 1 and 6 months. Third, group average cardiac and sympathetic baroreflex sensitivity seemed to be similar to that reported in normotensive individuals, 28, 47 supporting our impression that patients selected were not severely hypertensive. All told, given the negative outcome of the study by Brinkmann et al, 18 data are difficult to interpret and one cannot be sure of procedural success. 
Limitations
We are aware that the small patient numbers included in the human study and the variation in comorbidities in this cohort may limit some of our conclusions. However, our data add to and support recent published data regarding the effect of RDN on BP and SNA. 18 Furthermore, the addition of our animal cohort provides information regarding why RDN may not always be successful in humans, but is in animals. We suggest that the aggressive surgical denervation procedure possible in animal studies results in a more complete denervation, compared with the endovascular procedure used in humans.
Perspectives: One Size Does Not Fit All
Although we completed RDN in a small subset of patients, we found that only 50% of patients responded with a decrease >10 mm Hg in SBP at 6 months post-RDN. In addition, MSNA did not necessarily change in parallel to alterations in SBP after RDN in humans. The findings that the antihypertensive effect of RDN in SH rats was relatively small and the variable response observed in humans 18, 39, 40 support the contention that the etiology of resistant hypertension is multifactorial. In our human study and that of others, successful RDN treatment did not lower SBP to target levels in the majority of patients (<140 mm Hg; 38% at 6 months in Symplicity-1 14 ) or reduce BP to levels that allowed removal of antihypertensive medication. 9, 14 Clearly, other factors are involved and may include poor cerebral perfusion, 48, 49 excessive carotid body activity, 50, 51 activation of the innate immune system, 31, 52 and alterations in arterial baroreceptor input.
10,53
Thus, we believe that detailed autonomic and imaging (eg, renal anatomy, cerebral vessel anatomy) profiling of resistant hypertensive patients is required to provide an informed assessment of the likelihood that RDN will be successful and will lower SBP substantially toward target levels. Whether basal levels of MSNA (single and multiunit) will help in predicting who will respond to certain therapies is unclear and should be tested in patients where procedural success has been confirmed.
Conclusions
We confirm that RDN clearly has benefit to resting BP and MSNA in some resistant hypertensive patients. In our patients, baroreflex sensitivity was increased, which is linked to improved prognosis and mortality risk. Before we can predict the phenotype of patients who will respond robustly to RDN, studies assessing procedural success are imperative to move this treatment forward. On- • The improvement in cardiac and sympathetic baroreflex sensitivity seemed to be because of increased baroreflex sensitivity to falling blood pressures. This was found in both the rats and resistant hypertensive humans.
• The decrease in blood pressure and sympathetic activity in rats was more consistent than that in humans (all animals responded with a decrease in both). In humans, blood pressure was not reduced in all patients. In addition, alterations in sympathetic nerve activity did not appear to be in sync with changes in blood pressure. That is blood pressure reduced in some patients 1 and 6 months after renal denervation but sympathetic nerve activity increased progressively.
What Is Relevant?
• Improvements in baroreflex function after renal denervation in resistant hypertensive humans may help in improving the ability to buffer blood pressure during hypotensive episodes caused by some antihypertensive medications.
• Increased baroreflex sensitivity has been linked to improved cardiovascular risk and reduced rates of mortality.
• Differences between rat and human blood pressure reductions and changes in sympathetic activity support the contention that hypertension is multifactorial in humans. Thus, renal denervation may not help to decrease sympathetic activity (a significant contributor to end-organ damage) and blood pressure in all resistant hypertensive patients. Summary This is the first translational study that compares the response of blood pressure, sympathetic activity, and baroreflex sensitivity in spontaneously hypertensive rats after renal denervation to that in resistant hypertensive humans. Although renal denervation was of clear benefit to baroreflex function in rats and more importantly humans, not all humans responded with a decrease in blood pressure and sympathetic activity. The disparity between changes in blood pressure and sympathetic nerve activity in humans suggests that we do not fully understand the mechanism underlying reduction in blood pressure after renal denervation in humans. Furthermore, we provide additional evidence that renal denervation does not work to decrease blood pressure in all resistant hypertensive men and women. 
Novelty and Significance
